Media stories about Redhill Biopharma (NASDAQ:RDHL) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Redhill Biopharma earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.7425873366162 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Lookout Oversold stock: RedHill Biopharma Ltd. (RDHL) – Wall Street Morning (wallstreetmorning.com)
- RedHill Biopharma Announces Closing of Public Offering of its … – GlobeNewswire (press release) (globenewswire.com)
- RedHill Biopharma Reports 2017 Third Quarter Financial Results (finance.yahoo.com)
- RedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares (finance.yahoo.com)
- RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease (globenewswire.com)
Shares of Redhill Biopharma (RDHL) opened at $5.15 on Tuesday. Redhill Biopharma has a 1-year low of $5.09 and a 1-year high of $12.09.
Several brokerages recently issued reports on RDHL. Roth Capital reaffirmed a “buy” rating and set a $27.00 price target on shares of Redhill Biopharma in a report on Wednesday, October 4th. Zacks Investment Research raised shares of Redhill Biopharma from a “sell” rating to a “hold” rating in a report on Wednesday, September 20th. HC Wainwright reissued a “buy” rating and set a $36.00 target price (up from $33.00) on shares of Redhill Biopharma in a report on Wednesday, October 4th. Seaport Global Securities began coverage on shares of Redhill Biopharma in a report on Friday, October 6th. They set a “buy” rating and a $19.00 target price on the stock. Finally, UBS AG began coverage on shares of Redhill Biopharma in a report on Wednesday, September 13th. They set a “reduce” rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. Redhill Biopharma currently has an average rating of “Buy” and an average price target of $23.35.
Redhill Biopharma Company Profile
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.